Bio-Rad Laboratories is a medical devices business based in the US. Bio-Rad Laboratories shares (BIO) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $329.79 – a decrease of 1.08% over the previous week. Bio-Rad Laboratories employs 8,000 staff and has a trailing 12-month revenue of around $2.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $329.79 |
|---|---|
| 52-week range | $261.59 - $364.24 |
| 50-day moving average | $328.89 |
| 200-day moving average | $313.74 |
| Wall St. target price | $381.83 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-47.34 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $341.06 from 2024-10-14
| 1 week (2024-10-10) | 2.30% |
|---|---|
| 1 month (2024-09-17) | 2.22% |
| 3 months (2024-07-17) | 7.04% |
| 6 months (2024-04-17) | 17.26% |
| 1 year (2023-10-17) | 0.00% |
|---|---|
| 2 years (2022-10-17) | -15.61% |
| 3 years (2021-10-13) | N/A |
| 5 years (2019-10-17) | 343.45 |
Valuing Bio-Rad Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Rad Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Rad Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1905. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Rad Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Rad Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $514.2 million.
The EBITDA is a measure of a Bio-Rad Laboratories's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.6 billion |
|---|---|
| Operating margin TTM | 15.74% |
| Gross profit TTM | $1.6 billion |
| Return on assets TTM | 2.11% |
| Return on equity TTM | -17.41% |
| Profit margin | -51.73% |
| Book value | $240.39 |
| Market Capitalization | $9.5 billion |
TTM: trailing 12 months
We're not expecting Bio-Rad Laboratories to pay a dividend over the next 12 months.
Bio-Rad Laboratories's shares were split on a 2:1 basis on 7 March 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Rad Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Rad Laboratories shares which in turn could have impacted Bio-Rad Laboratories's share price.
Over the last 12 months, Bio-Rad Laboratories's shares have ranged in value from as little as $261.59 up to $364.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bio-Rad Laboratories's is 0.947. This would suggest that Bio-Rad Laboratories's shares are less volatile than average (for this exchange).
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.